The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Texas MPN Workshop 2021 | Avapritinib for indolent systemic mastocytosis
Prithviraj Bose, MBBS, MD Anderson Cancer Center, Houston, TX, discusses the potential of avapritinib to address the unmet needs of patients with indolent systemic mastocytosis. Dr Bose speaks on the ongoing pivotal PIONEER trial (NCT03731260) which seeks to investigate the efficacy of avapritinib for the treatment of indolent systemic mastocytosis. The primary endpoint of the study is to determine whether 30% of patients report an improvement in symptoms through a questionnaire. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.
Disclosures
Prithviraj Bose, MBBS, has received honoraria from Incyte, Celgene, BMS, CTI BioPharma, Sierra Oncology, Novartis, Blueprint Medicines and Kartos; and has received research support from Incyte, Celgene, BMS, CTI BioPharma, Constellation, Kartos, Blueprint Medicines, Astellas, Pfizer, Promedior and NS Pharma.
